Carotid Artery Disease Market – Insights on Upcoming Trends 2027

 The Global Carotid Artery Disease Market is expected to register a CAGR of 4.1% to reach USD 11,621.6 million till 2023.

Market Dynamics

Carotid artery disease is a condition in which plaques are developed in the arteries that supply blood to the brain, which often lead to strokes. The prominent factors that drive the market growth are increasing geriatric population, increasing adoption of an unhealthy lifestyle, and the popularity of over-the-counter (OTD) drugs. However, the high cost of diagnostics and surgeries and stringent government regulations for the carotid artery disease are likely to restrain market growth over the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6301 

Carotid stenosis, also known as carotid artery disease, is characterized by the narrowing of the carotid arteries, the primary blood vessels that carry oxygenated blood to the brain. The narrowing is caused by plaque or fatty deposits along the inner wall of the artery, resulting in reduced blood flow to the brain. Over time, plaque deposits inside the inner wall of the artery can form a large mass that narrows the lumen, the inside diameter of the artery, and cause a complete blockage of the artery.

High prevalence of carotid artery disease among the geriatric population, increase in prevalence of diabetes, and a surge in tobacco consumption is projected to drive the global carotid artery disease market during the forecast period.  According to the WHO, stroke accounts for 17 million deaths across the globe each year. Over 500,000 new cases of stroke are reported in the U.S. each year, and carotid stenosis is estimated to cause 20% to 30% of these. Hence, the demand for early diagnosis and treatment to prevent deaths from stroke is high. However, the high cost of treatment and strict government regulations required for the approval of new and advanced technological devices and drugs are anticipated to restrain the market in the near future. Increase in patient awareness about early detection, prevention, and treatment of heart attacks and stroke are also expected to boost the global carotid artery disease market.

Market Research Future (MRFR) recognizes the following companies as the key players in the global carotid artery disease market that includes:  W. L. Gore & Associates, Inc., Becton, Dickinson and Company, Terumo Corporation, Hitachi, Ltd, Silk Road Medical, Inc., Abbott, Medtronic, Stryker Corporation, Cardinal Health, Boston Scientific Corporation.

Segment analysis

The global carotid artery disease market trends by treatment & diagnosis is segmented into treatment and diagnosis. The treatment is segmented into medications and surgical procedures. The medications are further segmented into cholesterol-lowering statins, antiplatelet drugs, and antihypertensive drugs. The surgical procedures are further segmented into carotid endarterectomy, carotid artery angioplasty & stenting, and carotid artery bypass.

The global carotid artery disease market by end user is segmented into hospital & clinics, ambulatory surgical centers, pharmacies, and others.

Regional Analysis

On the basis of region, the global carotid artery disease market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. Rise in prevalence of cardiovascular disorders, increase in disorders such as ischemic stroke, peripheral vascular lesions, growth in geriatric population, technological advancement, and a surge in adoption rates of minimally invasive surgeries. However, factors such as complications associated with stents and stringent regulations related to approval processes restrain market growth. Furthermore, the development of biocompatible stents and rise in the emergence of carotid artery stents with new technology drive the market growth during the forecast period.

North America is expected to dominate the market. According to the Healthmetrics Health Organization, stroke is a leading cause of serious long-term disability in the US, and each year, about 795,000 people experience a new or recurrent stroke. Approximately, 610,000 of these are first attacks, and 185,000 are recurrent attacks.

Europe currently holds a significant share in the global carotid artery disease market. According to European Heart Network, each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU).

Asia-Pacific is the fastest growing region in the global carotid artery disease market owing to developing economies of China, India, and South Korea, which are emerging as major destinations for outsourcing clinical trials, drug manufacturing, and pathology testing.

The Middle East and Africa market is projected to hold the least share in the global carotid artery disease market. In this region, the Middle East is anticipated to dominate owing to the presence of countries such as Egypt, Saudi Arabia, and others.

Key Findings of the Study:

• Global carotid artery disease market is projected to reach over 11,621.6 million by 2023 with 4.1% CAGR during the review period of 2018 to 2023
• The Americas accounted for the largest share due to the presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the carotid artery disease market in America.
• The treatment & diagnosis segment by treatment is projected to value 8,899.3 million by 2023.
• Some of the additional players operating in the carotid artery disease market are Johnson & Johnson, MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, InspireMD, Impulse Dynamics and AstraZeneca PLC.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/carotid-artery-disease-market-6301 

Drug of Abuse Testing Market: Recent Industry Trends and Projected Industry Growth, 2020– 2027

 What is drug abuse testing market technilogy ? With people being inclined more towards an unhealthy lifestyle, it is noticed that intake of alcohol and illicit drugs has increased in the past few years. Diagnosing the drug addiction in patients, the types of drug involved, evaluation of drug abuse, etc. are the thesis of the drug abuse testing market. Many rehabilitation centers are equipped with highly qualified doctors, drug counselors, psychologists, and psychiatrists who deal with patients suffering from drug addiction. Patients go under lab tests of urine, blood, breath, and others regularly to keep track of drug intake so that contains the addiction.

Youth is the most affected generation of drug abuse because of unawareness of excessive use of alcohol and drugs. The government of various countries around the world has become active in creating drug testing centers and hospitals. Many road accidents have become common because of alcohol and drug usages, increasing the death-rate in the countries. The global drug abuse testing market is estimated to register a CAGR of 7.77% by the year 2025 with more than 6,673.3 million US dollars invested through local and private sectors.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1930 

Global Drug of Abuse Testing Market - Overview

The use of illicit drugs is rising every year globally and has become a big concern for countries including the U.S., the U.K. Japan, Germany, India and China. Illicit drugs in use include heroin, cannabis, cocaine, ecstasy and amphetamine. Global cocaine seizures increased to 671 tons in 2012, compared with the 634 tons seized in 2011. The main increase in the quantities of cocaine seized was in South America and Western and Central Europe. Some of the new psychoactive substances (NPS) like, phenethylamines, ketamine, piperazine and tryptamines, are also being used widely in the drug market.

Further Drug trafficking is a global illicit trade involving the cultivation, manufacture, distribution and sale of substances which are subject to drug prohibition laws. According to United Nations Office on Drugs and Crime (UNODC) estimates, drug trafficking is increasing worldwide due to rising demand of illicit drugs (mainly heroin, cocaine and amphetamines). World heroin consumption and seizures represent an annual flow of 430 tons to 450 tons of heroin in the global heroin market.

According to data from the UNODC and European crime-fighting agency Europol, the annual global drugs trade is worth around $435.0 billion a year, with the annual cocaine trade worth $84 billion. With the exception of opiate use, use of all other groups of substances (opioids, cannabis, cocaine, ATS and ecstasy) remains at level higher than the global average in the region. In the U.S., illicit drug use by persons aged 12 years or older reached the highest level in the past 10 years, increasing from 15.0% in 2011 to 16.0% in 2012.

The overall demand for drug of abuse testing is rising and the same is being used mostly by healthcare service providers, public and private organizations and other government agencies. The two major technologies used for onsite screening testing and laboratory testing of drug of abuse are immunoassay technique and chromatography.

Global Drug of Abuse Testing Market – Industry Updates

In November 2017, Thermo Fisher Scientific announced the newest library update for the Thermo Scientific TruNarc handheld narcotics analyser which can now detect Carfentanil. As part of the software update, the TruNarc analyzer adds 45 new substances, including 14 new forms of fentanyl, to its onboard library.

In August 2016, Thermo Fisher Scientific announced that a new immunoassay for the specific detection of hydrocodone has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA).

Global Drug of Abuse Testing Market - Regional Analysis

In North America, the usage of cocaine has been declining since 2006, partly due to a sustained shortage. However, more recently, a slight increase in prevalence of cocaine has been observed in the U.S., as there has been an increase in maritime seizures.

In Europe, cannabis is by far the most commonly consumed illicit substance, with an estimated 24 million users (4.3% of those aged 15 years to 64 years), followed by cocaine with 3.7 million users in 2013.

In Europe, the market has changed over the past decade, with cannabis herb produced locally or regionally now gaining ground over cannabis resin, largely sourced from Morocco, which previously was the dominant cannabis substance in Europe.

It appears that the flow of heroin along the long-established Balkan route, from Afghanistan to Western and Central Europe via Iran and Turkey, has declined in recent years. Some of the factors contributing to the decline in seizures along this route include the success of law enforcement authorities in key transit countries and a decline in demand in the destination market.

By far the highest prevalence of injecting drug use, with a rate 4.6 times the global average, is found in Eastern/South-Eastern Europe, where 1.3% of the population aged 15-64 are estimated to have recently injected drugs. Although the general public may perceive cannabis to be the least harmful illicit drug, between 2003 and 2012 the proportion of total treatment admissions for cannabis increased in Western and Central Europe, from 19% to 25%.

In Asia, it is estimated that cannabis is the most common illicit substance, with an annual prevalence of use of 1.9%, followed by ATS (excluding ecstasy) at 0.7%, ecstasy at 0.4%, opiates at 0.4% and cocaine at 0.1%, among those aged 15-64 years. The use of methamphetamine continues to rise in most of the countries in East and South-East Asia, with accompanying seizures of methamphetamine in pill and crystalline forms reaching record levels in 2012. It has been indicated that in East and South-East Asia, the use of ATS has both increased and diversified. ATS has been ranked among the three predominately used drug types in countries in the sub-region since 2009.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/drug-abuse-testing-market-1930 

Mastitis Market: Recent Industry Trends and Projected Industry Growth, 2020– 2027

 The Global upcoming Mastitis Market trends expected to register a CAGR of 15.07% to reach USD 18,338.80 Million till 2023. Mastitis is an infection in the tissue of one or both mammary glands inside the breast. It usually affects women who are breastfeeding, and it results from a blocked or a plugged duct. In bovine, mastitis is the inflammation of the mammary gland and udder tissue due to bacterial invasion of the teat canal by a variety of bacterial sources present on the farm, and can also occur as a result of chemical, mechanical, or thermal injury to the cow's udder.

The rising cases of breast cancer, increasing rate of pregnancy, and unhygienic barn conditions causing contagious mastitis in bovines across the globe is expected to enhance the market growth. However, the lack of awareness and complications in diagnosis due to similar symptoms of breast cancer & mastitis are projected to curb the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5379 

Regional Analysis

The Americas mastitis market is expected to show extensive growth owing to increasing number of patient population for mastitis, and technological advancement in the healthcare.  Moreover, high health care spending and increasing government support for research & development are expected to boost the market growth.

Europe holds the second largest share of the global market. The increasing focus of various government agencies on treating mastitis, and increasing investment in healthcare domain to improve treatment methods of rare diseases will fuel the growth of the market. The growing public awareness will boost the European market.    

The Asia Pacific is the fastest growing mastitis market across the globe. Japan holds the major share of the regional market due to the availability of technology and huge healthcare spending. Rapidly developing the economy, increasing healthcare expenditure, and government initiatives for research & development are projected to drive the market in China and India over the assessment period.  Alongside, there is a huge growth outlook for the market in the developing countries as these countries are encouraging research and development in healthcare management.

The Middle East and Africa hold the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market whereas, the African region is expected to witness a moderate growth.

Segmentation

The global mastitis market is segmented on the basis of types, diagnosis, treatment, and end-users. Based on the types, the market is segmented into contagious mastitis and environmental mastitis. On the basis of the diagnosis, the market is segmented into the physical examination and others. On the basis of the treatment, the market is segmented into antibiotics, pain relievers, surgery, and others. The pain relievers are further segmented into acetaminophen, ibuprofen, and others. Moreover, the acetaminophen is segmented into Tylenol and others. Ibuprofen is further segmented into Advil, Motrin IB, and others. On the basis of the end users, the market is segmented into hospital & clinics, research centers, and others.

Key Players

Some of key the players in the market are Pfizer (U.S.), Novartis AG (Switzerland), Oncogenex (U.S.), Apthera Inc (U.K), BioNumerik Pharmaceuticals (U.S.), Oncothyreon Inc (US), Astellas (Japan), Bipar Sciences (U.S.), Puma Biotechnology (U.S.), Sanofi S.A. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (U.K), Genentech (U.S), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc. (U.S.), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mastitis-market-5379 

Global MRSA Drugs Market 2020 Industry Key Players, Trends, Sales, Supply, Demand, Analysis & Forecast By 2027

 The Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market size is expected to register a CAGR of 4.4% to reach USD 4,312.2 million till 2023. Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen. This infection is generally associated with invasive procedures such as surgeries, intravenous tubing, and sometimes through the skin to skin contact. MRSA drugs are used to kill or restrain methicillin-resistant staphylococcus aureus infection.

The increase in the prevalence of MRSA infections and number of hospitals, growing awareness about a bacterial infection, and increase in immuno-compromised population are expected to enhance the market growth. However, the high cost of novel MRSA drugs and hospital readmissions reduction program is projected to curb the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2102 

Global MRSA Drugs Market Players

Some of the key players profiled in the report are Merck KGaA, Olon, Allergan, Baxter, Theravance Biopharma, Pfizer, Mylan N.V, Novartis, and others.

Regional Analysis

The Americas accounts for a significant market share owing to high expenditure on the health care. The fastest uptake of new drugs in the US drives the MRSA drugs market. Furthermore, concentration of the major healthcare companies in the developed countries of this region coupled with large insurance penetration is adding fuel to the market growth. Moreover, the US expend high amount on its healthcare, which accounts for 16% of total GDP that also increases the sale in MRSA drugs market.

Europe is the second largest market in the world due to high income and strong healthcare penetration. The European market growth is led by countries such as Germany and France. Italy is expected to be the fastest growing region over the assessment period. The strong pharmaceutical industry in Germany is a primary driver behind the dominance of this country in Europe. Southern Europe has a considerable high prevalence of MRSA as compared to Scandinavian region countries such as Iceland, Norway etc. which is driving the market faster in these nations.

Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. However Asian countries such as Indonesia, Vietnam, Japan, South Korea, Philippines, and Sri Lanka have higher prevalence and are expected to contribute highly to the market growth. The growing penetration of healthcare insurance in the Asia Pacific region is expected to drive the future MRSA drugs market in the region.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions, and poor healthcare development.

Taste the market data and market information presented through more than 50 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Global MRSA drugs Market” Research Report – Forecast till 2023.

Segmentation

The global MRSA drugs market has been segmented on the basis of drug class, MRSA types, disease indications, and end user.

Based on the drug class, the market has been segmented as sulfa drugs, tetracyclines, oxazolidinones, glycopeptide antibiotics, and other.

Based on the MRSA types, the market has been segmented as hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA).

Based on the disease indications, the market has been segmented as skin infections, bone and joint infections, bacteremia, animal infections, and others.

Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mrsa-drugs-market-2102 

Egg Allergy Market Current Trends, SWOT Analysis, Strategies, Industry Challenges, Business Overview and Forecast Research Study 2027

 The egg allergy market is emerging rapidly in the global economy and will further rise to extreme heights in the near future. The egg allergy market size is estimated to reach around USD 2304.3 million by 2023, with a predicted CAGR or compound annual growth rate of 7.10 percent in the forecast period from 2018 to 2023.

The global egg allergy market is rising at a faster rate due to the surge of egg allergy incidence taking place in recent times. According to the British Society for Allergy & Clinical Immunology data, the ubiquity of food allergies has grown, and 6 to 8 percent of children getting affected by the same. These allergies affect both infants as well as adults and can happen in few minutes or take few hours. Egg allergy symptoms in adults can happen due to egg overreaction by the body's immune system. The body's immune system identifies egg protein as hazardous and triggers an allergic reaction. The extreme ubiquity of egg allergies will expand the egg allergy market size in the forecast years.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4734 

Segmentation:
The Global Egg Allergy Market has been segmented based on age group, diagnosis & treatment, and end user.

By age group, the Global Egg Allergy Market has been segmented into children (0-18 years and adults (18+ years).

By diagnosis & treatment, the global egg allergy market has been segmented into diagnosis and treatment. The diagnosis segment has been further segmented into skin test, blood test, food challenge, and others.  The treatment segment has been further segmented into medication and oral immunotherapy. The medication sub-segment has been further segmented into antihistamine, epinephrine, and others.

By end user, the Global Egg Allergy Market has been segmented into hospitals & clinics, diagnostic centers, research institutes, and others.

Regional Analysis:
Regionally, the Global Egg Allergy Market is spanned across the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa. The Global Egg Allergy Market is dominated by the Americas which has been further segmented into North America and South America. North America accounts for the maximum share of the North America market. Government support in the form of favorable legislation, coupled with the concentration of prominent market players in the region aid the growth of the market. Europe is the second largest market for egg allergy. Increasing prevalence of egg allergy in the region is a prime factor in boosting the market growth in Europe. The European Academy of Allergy and Clinical Immunology (EAACI) estimates that the number of people suffering from food allergy has increased to 17 Million in the last ten years which generates considerable demand for diagnosis and treatment. Besides, rigorous R&D efforts and high expenditure on healthcare could drive the market in Europe.

APAC is poised to emerge as the fastest growing market for egg allergy at a CAGR of 8.71% over the forecast period. Growing innovation in the field of allergen-free food products, growing awareness, and faster adoption of new technologies spur the market in APAC. The MEA market is anticipated to register a CAGR of 5.70% over the forecast period due to limited access to healthcare in the developing countries. However, the Middle East market is likely to showcase moderate growth on account of improving healthcare infrastructure.

Competitive Landscape:
Mylan N.V. (US), Genetech, Inc. (US), Sanofi (France), Creative Diagnostics (US), Alletess Medical Laboratory (US), HYCOR Biomedical (US), Kaleo, Inc. (US), Impax Laboratories, Inc (US), Kaleo, Inc. (US), Quest Diagnostics (US), Impax Laboratories (US), Imutest Ltd. (UK), and ImmuneTech (US) are the key players in the global egg allergy market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/egg-allergy-market-4734 

Automated Hospital Beds Market Growth Insight Analysis 2020-2027

 The Global Automated Hospital Beds Market size is expected to register a CAGR of 5.97% and is anticipated to reach USD 2,553.4 million by 2023. 

Automated hospital beds are specially designed for hospitalized patients in need of some form of health care services. These hospitals beds have special features both for the comfort and well-being of the patient and for the convenience of health care workers. Most common features of automated hospital beds are automated adjustable height for the entire bed including the head and the feet, adjustable side rails, and electronic buttons to operate both the bed and other nearby electronic devices.

The increase in the number of various acute and chronic disorders, rising geriatric population, increased number of obese people, continuous development in the designs of the hospital beds for the betterment and more comfort of the patients, and rising healthcare expenditure are the major drivers propelling market growth. However, the high cost of automated hospital beds and expensive maintenance of automated hospital beds are hampering the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4250 

Automated hospital beds are more convenient and user-friendly than the traditional hospital beds. Automated hospital beds are designed to meet needs of the patients proficiently for different situations. The hospital electric beds are highly adjustable, comfortable and flexible. Developed regions such as the Americas and Europe accounted for the major market share due to technological development in the healthcare sector. These beds work with minimal assistance and are self-controlled, which makes handling them easy, a less laborious task than the manual beds.

Various medical emergencies such as accidents on roads, industrial mishaps, wars, and natural calamities which provides huge opportunities for the hospitals to improve their promptness to tackle such medical emergencies. Hospitals and other healthcare emergency centres have increased their required facilities to handle emergencies which will fuel the market growth. Furthermore, the growth of emergency departments to meet the rising medical emergencies will drive the demand for automated hospital beds. For instance, many hospitals have separate rooms for operating emergency cases, and in case of surgery with the help of automated hospital beds surgeries can be performed immediately.

The increasing prevalence of life-threating diseases drives admission rates in healthcare facilities. To meet the unmet demand for healthcare facilities, manufacturers and suppliers are introducing advanced automated products and thus increasing the market penetration in the automated hospital beds sector. The rising incidence of life-threating diseases in Asia Pacific and the Middle East & Africa has prompted suppliers and manufacturers to expand their market reach and to enter in emerging markets. According to the Centers for Disease Control and Prevention (CDC), life-threatening or chronic diseases such as stroke, heart diseases, diabetes, and chronic respiratory diseases, kidney diseases were the leading cause of death in 2014. For example, according to the Center of Disease Control and Prevention, each year, nearly 4.9 million adults with diagnosed kidney disease.

ArjoHuntleigh, Gendron Inc., Hill-Rom, Invacare Corporation, Linet spol. s r.o., Medline Industries, Inc., Paramount Bed Holdings Co., Ltd., and Stryker and others are some of the major players in the Global Automated hospital beds Market.

Global Automated hospital beds Market   - Regional Analysis

Market opportunities are those unexploited factors that are expected to boost the growth of the market. These factors can be referred to as the untapped drivers of the market. The major opportunities for the automated hospital beds are the introduction in developing economies.

Introduction of smart hospital bed is one of the emerging opportunities for the global automated hospital beds market. Smart bed advancements will improve patient safety and comfort throughout the hospital stay.

The demand for the automated hospital beds is increasing due to its easier and more sophisticated for patients in developing countries that include Asia Pacific and the Middle East & African countries. These developing countries are suffering with immense disease burden. These diseases include asthma, cardiac failure, chronic obstructive pulmonary disease, chronic kidney disease, coronary artery disease, multiple sclerosis, Parkinson’s disease and others resulting increasing in-patient population in hospitals.

Governments of few developing countries have taken educational initiatives and projects such as the Janala Project (Bangladesh), ProjectABC (Nigeria), Tostan (Senegal), Yoza (South Africa), and BridgeIT (Tanzania) among others. These programs are focused to improve literacy and create awareness about health that help to increase the understanding of people and raises chances of becoming technically mature. These factors will indirectly boost the market growth for automated hospital beds.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/automated-hospital-beds-market-4250 

Capillary Blood Collection Devices Market Current Trends, SWOT Analysis, Strategies, Industry Challenges, Business Overview and Forecast Research Study 2027

 

Market Overview

Global Capillary Blood Collection Devices industry is anticipated to record a CAGR of 10.3% while garnering a market value of USD 778.38 Million by 2027, asserts Market Research Future (MRFR).

Impact of COVID-19

The outbreak of COVID-19 brought a significant impact on the capillary blood collection devices industry. The lockdown imposed during the pandemic hampered the production and supply chain owing to the temporary shutdown of the manufacturing units.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4213 

Key Players in the Malocclusion Market

Some of key the players in the capillary blood collection devices market are F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories, Novo Nordisk A S, Becton Dickinson and Company, Medtronic PLC, B. Braun Melsungen AG, Thermo Fisher Scientific Inc., Terumo Corporation, Ypsomed Holding AG, HTL-STREFA S.A., Sarstedt AG & Co, Owen Mumford Ltd., Greiner Bio-One, Improve Medical, Chengdu Rich Science Industry Co., Ltd., Weigao Group, Nipro, Medigard, Weihai Hongyu Medical Devices, and others.

Regional Analysis

The global capillary blood collection devices market is segmented on the basis of regions, namely, America, Europe, Asia Pacific, and the Middle East & Africa.

The Americas dominate the capillary blood collection devices market owing to the high healthcare expenditure, growing demand for diagnosis of chronic diseases, and well-developed technology. The incidence of contagious diseases is increasing rapidly on a global level, some of these diseases include Hantavirus pulmonary syndrome, HIV/AIDS, Lyme disease, hemolytic uremic syndrome. The need to monitor along with the requirement of advanced techniques for diagnostic testing of non-contagious diseases such as diabetes mellitus, chronic kidney diseases, lung disease, and some heart diseases are expected to impact the growth of the global capillary blood collection devices market.

Europe holds the second position in the capillary blood collection devices market. It is expected that the economic support provided by the government and private bodies for R&D, increasing the incidence of diabetes, and presence of leading market players are propelling the growth of the capillary blood collection devices market in the European region. For instance, Medtronic, an Ireland based company, is a global healthcare solution company that provides a multitude of products. The product. In January 2015, the company completed the acquisition of Covidien plc tap new markets.

Asia Pacific region is projected to be the fastest growing region during the forecast period. Rapidly improving technology, and rising prevalence of Diabetes drive the growth of this market in Asia Pacific region. According to the 2013 statistics suggested by The Diabetes Atlas, around 366 million people are affected by diabetes in the Asian region.

The Middle East and Africa hold the least share of the capillary blood collection devices market owing to the presence of poor and slow developing countries, especially, in the African region.

Segmentation

The global capillary blood collection devices market is segmented on the basis of material, type of devices, and end user.

On the basis of the material, the market is classified into plastic, glass, stainless steel, and others.

On the basis of type of devices, the market is segmented into blood collecting tubes and collector, lancets, and warming devices.

On the basis of end-user, the market is segmented into hospitals, clinics, diagnostic centers and pathology laboratories, home diagnostics, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/capillary-blood-collection-devices-market-4213